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Abstract
Nitric oxide (NO) is an endogenous vasodilator as well as natural inhibitor of platelet adhesion/
activation. Nitric oxide releasing (NOrel) materials can be prepared by doping an NO donor
species, such as diazeniumdiolated dibutylhexanediamine (DBHD/N2O2), within a polymer
coating. The inherent hemocompatibility properties of the base polymer can also influence the
efficiency of such NO release coatings. In this study, four biomedical grade polymers were
evaluated in a 4 h rabbit model of thrombogenicity for their effects on extracorporeal circuit
thrombus formation and circulating platelet count. At the end of 4 h, Elast-Eon E2As was found to
preserve 58% of baseline platelets versus 48, 40, and 47% for PVC/DOS, Tecophilic SP-60D-60,
and Tecoflex SG80A, respectively. Elast-Eon also had significantly lower clot area of 5.2 cm2
compared to 6.7, 6.1, and 6.9 cm2 for PVC/DOS, SP-60D-60, and SG80A, respectively. Based on
the results obtained for the base polymer comparison study, DBHD/N2O2-doped E2As was
evaluated in short-term (4 h) rabbit studies to observe the NO effects on prevention of clotting and
preservation of platelet function. Platelet preservation for this optimal NO release formulation was
97% of baseline after 4 h, and clot area was 0.9 cm2 compared to 5.2 cm2 for controls,
demonstrating that combining E2As with NO release provides a truly advanced hemocompatible
polymer coating for extracorporeal circuits and potentially other blood contacting applications.
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1. Introduction
The hemocompatibility of blood-contacting medical devices (e.g., extracorporeal circuits,
catheters, stents, grafts, etc.) is still a challenge, despite decades of research.1-3
Extracorporeal circulation (ECC) includes a wide variety of devices, from short-term
hemodialysis and cardiopulmonary bypass (several hours), to extracorporeal life support
(ECLS) (days to weeks).4 The most common complications with ECLS devices are bleeding
(7-34%) and thrombosis (8-17%).5 In a clinical setting, these extracorporeal devices require
the use of systematic anticoagulation (e.g., heparin) to avoid device failure.6 Systemic
*Corresponding Authors: Hitesh Handa Department of General Surgery University of Michigan 1150 W. Medical Center Dr. Ann
Arbor, MI 48109 Telephone: (734) 615-5357 hhanda@umich.edu. Mark E. Meyerhoff Department of Chemistry University of
Michigan 930 N. University Ave Ann Arbor, MI 48109 Telephone: (734) 763-5916 mmeyerho@umich.edu.
NIH Public Access
Author Manuscript
J Mater Chem B Mater Biol Med. Author manuscript; available in PMC 2015 February 28.
Published in final edited form as:
J Mater Chem B Mater Biol Med. 2014 February 28; 2(8): 1059–1067. doi:10.1039/C3TB21771J.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
infusion of anticoagulants, such as heparin, is known to be the cause of hemorrhage,
thrombocytopenia, and thrombosis.7 Despite these complications, heparin is still used as the
standard in anticoagulation therapy for patients on ECC. Biomaterial related thrombosis is a
complex process, where the initial biological response when blood comes in contact with a
foreign surface is protein adsorption, which is followed by platelet adhesion and activation,
leading to thrombus formation. One approach to improve the hemocompatibility of a surface
is to prevent platelet adhesion, which is desirable for improving clinical outcomes. Nitric
oxide (NO) is a well-known inhibitor of platelet activation and adhesion that is released
from the endothelium lining of blood vessels. The amount of NO released from normal and
stimulated endothelium has been estimated to between 0.5-4.0 ×10−10 mol cm−2 min−1.8
Hence, one potential strategy to decrease the level or completely avoid systemic
heparinization is to develop coatings that mimic the endothelium with respect to NO release
at physiological levels.
Due to the short lifetime of NO under physiological conditions, a wide number of NO donor
molecules have been studied, including S-nitrosothiols9-11 and N-diazeniumdiolates,12-15
and these species have been used to develop polymeric materials that mimic this NO release
from normal endothelium. Diazeniumdiolates release NO through thermal16 and proton17
driven mechanisms. Diazeniumdiolated dibutylhexanediamine (DBHD/N2O2) has proven to
be an excellent NO donor when incorporated into polymer materials, however the release of
NO creates lipophilic amines which raises the pH within the polymer matrix and effectively
turns off the NO release.14, 15 Prior work demonstrated that tetrakis-(p-chlorophenyl)-borate
could be used as an additive to prolong the NO release up to a few days from the DBHD/
N2O2-based coatings.12, 14 However, this additive did not enable the release of the entire
payload of NO from the polymer coatings and was also found to be cytotoxic towards
endothelial and smooth muscle cells.18 Recently, it was shown that ester-capped poly(lactic-
co-glycolic acid) (PLGA), a bioabsorbable polymer, can be used as a small additive to
DBHD/N2O2-based coatings and greatly extends the NO release profile of these coatings.15
PLGA hydrolyzes and continuously generates lactic and glycolic acid, which can
compensate for the pH elevation from the organoammonium hydroxide (resulting from the
reaction between the lipophilic amines and water), thereby controlling the pH within the
organic polymer phase and sustaining the NO release up to 14 d.15, 19
Previously, our group has observed preservation of platelets and reduced thrombus area in a
rabbit model of ECC with NO release coatings using DBHD/N2O2 doped poly(vinyl
chloride)/dioctyl sebacate (PVC/DOS) as the base polymer.12, 15 However, the inherent
hemocompatiblity properties of the base polymers used in combination with NO release can
have a direct effect on the ultimate efficacy in preventing thrombus formation. In this study,
we evaluate the degree of platelet consumption and thrombus formation of four biomedical
grade polymers (poly(vinyl chloride) (PVC)/dioctyl sebacate (DOS), Tecophillic
SP-60D-60, Elast-Eon E2As, and Tecoflex SG80A) in a rabbit thrombogenicity model using
an arterio-venous (A-V) shunt. The polymer yielding the best inherent hemocompatible
properties was then used for the NO release studies by doping with DBHD/N2O2 and ester-
capped PLGA additive, which was then evaluated in the 4 h rabbit model for effects on
platelet consumption and thrombus formation.
2. Materials and Methods
2.1. Materials
TygonTM poly(vinyl chloride) (PVC) tubing was purchased from Fisher Healthcare (Houston,
TX). Tecophilic SP-60D-60 and Tecoflex SG-80A were obtained from Lubrizol Advanced
Materials Inc. (Cleveland, OH). Elast-EonTM E2As was a product of AorTech International,
plc (Scoresby, Victoria, Australia). Anhydrous tetrahydrofuran (THF), anhydrous
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acetonitrile, sodium chloride, potassium chloride, sodium phosphate dibasic, and potassium
phosphate monobasic were purchased from Sigma-Aldrich Chemical Company (St. Louis,
MO). Poly(D,L-lactide-co-glycolide) 5050DLG7E was obtained from SurModics
Pharmaceuticals Inc. (Birmingham, AL). Human P-selectin glycoprotein (CD62P) PE and
IgG1 PE were obtained from AbD Serotec (Raleigh, NC). N,N’-Dibutyl-1,6-hexanediamine
(DBHD) was purchased from Alfa Aesar (Ward Hill, MA). DBHD/N2O2 was synthesized
by treating DBHD with 80 psi NO gas purchased from Cryogenic Gases (Detroit, MI) at
room temperature for 48 h, as previously described.14 Phosphate buffered saline (PBS), pH
7.4, containing 138 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate, was used for all in
vitro experiments.
2.2. Preparation of coated ECC loops
The ECC configuration employed in the in vivo rabbit study was previously
described.9, 12, 15 Briefly, the ECC consisted of a 16-gauge and 14-gauge IV polyurethane
angiocatheters (Kendall Monoject Tyco Healthcare Mansfield, MA), two 16 cm in length ¼
inch inner diameter (ID) Tygon™ tubing and an 8 cm length of 3/8 inch ID Tygon™ tubing
that created a thrombogenicity chamber where thrombus could form more easily due to more
turbulent blood flow.
Base polymer coated control ECCs—Polymer control loops were coated with E2As,
SG80A, SP60D60, or PVC/DOS solutions, as shown in Fig. 1A. All the control loops
contained 2 coats of the polymer/THF solution (2500 mg in 15 mL).
NOrel coated ECCs—NOrel loops were prepared with E2As coating containing 25 wt%
DBHD/N2O2 as the NO donor, and 10 wt% 5050DLG7E PLGA additive, as shown in Fig.
1B. The NOrel solution was prepared by dissolving 1600 mg E2As and 250 mg PLGA in 15
mL THF. DBHD/N2O2 (625 mg) was then dispersed within the polymer cocktail by
sonication for 30 min to obtain a slightly cloudy dispersion of the diazeniumdiolate in the
solution. The PVC tubing was first coated with 2 layers of the NOrel solution, followed by 1
coat of the E2As control solution (2500 mg in 15 mL).
All ECC loops were allowed to air dry for 1 h between each coat. The completely coated
ECC was assembled together using THF, starting with the 16-gauge angiocatheter, one 15
cm length ¼ inch ID tubing, the 8 cm length thrombogenicity chamber, the second 15 cm
length ¼ inch ID tubing and finally the 14-gauge angiocatheter. The angiocatheters were
interfaced with tubing using two luer-lock PVC connectors. The assembled ECC loops were
dried for 1 d under ambient conditions and then under vacuum for 48 h.
2.5. NO release measurements
Nitric oxide released from the samples was measured using a Sievers chemiluminescence
Nitric Oxide Analyzer (NOA), model 280 (Boulder, CO).9, 12, 14, 15 A sample was placed in
4 mL PBS buffer at 37°C. Nitric oxide liberated from the sample was continuously swept
from the headspace of the sample cell and purged from the buffer with a nitrogen sweep gas
and bubbler into the chemiluminescence detection chamber. The flow rate was set to 200
mL/min with a chamber pressure of 5.6 Torr and an oxygen pressure of 6.0 psi.
2.6. The 4 h rabbit thrombogenicity model
Rabbit thrombogenicity model protocol—The animal handling and surgical
procedures were approved by the University Committee on the Use and Care of Animals in
accordance with university and federal regulations. A total of 22 New Zealand white rabbits
(Myrtle’s Rabbitry, Thompson’s Station, TN) were used in this study. All rabbits (2.5-3.5
kg) were initially anesthetized with intramuscular injections of 5 mg/kg xylazine injectable
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(AnaSed® Lloyd Laboratories Shenandoah, Iowa) and 30 mg/kg ketamine hydrochloride
(Hospira, Inc. Lake Forest, IL).
Maintenance anesthesia was administered via isoflurane gas inhalation at a rate of 1.5-3%
via mechanical ventilation which was done via a tracheotomy and using an A.D.S. 2000
Ventilator (Engler Engineering Corp. Hialeah, FL). Peek inspiratory pressure was set to 15
cm of H2O and the ventilator flow rate set to 8 L/min. In order to aid in maintenance of
blood pressure stability, IV fluids of Lactated Ringer’s were given at a rate of 10 mL/kg/h.
For monitoring blood pressure and collecting blood samples, the rabbits’ right carotid artery
was cannulated using a 16-gauge IV angiocatheter (Jelco®, Johnson & Johnson, Cincinnati,
OH). Blood pressure and derived heart rate were monitored with a Series 7000 Monitor
(Marquette Electronics Milwaukee, WI). Body temperature was monitored with a rectal
probe and maintained at 37°C using a water-jacketed heating blanket. Prior to placement of
the arteriovenous (AV) custom-built extracorporeal circuits, the rabbit left carotid artery and
right external jugular vein were isolated and baseline hemodynamics as well as arterial
blood pH, pCO2, pO2, and total hemoglobin were measured using an ABL 825 blood-gas
analyzer. In addition, baseline blood samples were collected for platelet and total white
blood cell (WBC) counts which were measured on a Coulter Counter Z1 (Coulter
Electronics Hialeah, FL). Activated clotting times (ACT) were monitored using a
Hemochron Blood Coagulation System Model 801 (International Technidyne Corp. Edison,
NJ), platelet function was assessed using a Chrono-Log optical aggregometer model 490
(Havertown, PA).
After baseline blood measurements, the custom-built ECC was placed into position by
cannulating the left carotid artery for ECC inflow and the right external jugular vein for
ECC outflow. The flow through the ECC was initiated by unclamping the arterial and
venous sides of ECC and blood flow in circuit was monitored with an ultrasonic flow probe
and flow meter (Transonic HT207 Ithaca, NY). Animals were not systemically
anticoagulated during the experiments.
Blood sampling—Rabbit whole blood samples were collected in non-anticoagulated 1
mL syringes for ACT, 3.2% sodium citrate vacutainers (Becton, Dickinson. Franklin Lakes,
NJ) in 3 mL volumes for cell counts, aggregometry, and 1 mL syringes containing 40 U/mL
of sodium heparin (APP Pharmaceuticals, LLC Schaumburg, IL) for blood-gas analysis.
Following the initiation of ECC blood flow, blood samples were collected every hour for 4 h
for ex vivo measurements. Samples were used within 2 h of collection to avoid any
activation of platelets, monocytes or plasma fibrinogen.
Platelet aggregometry—Rabbit platelet aggregation was assayed based on the Born’s
turbidimetric method using a Chrono-Log optical aggregometer. Briefly, citrated blood
(1:10 blood to 3.8% sodium citrate) was collected (6 mL) and platelet-rich plasma (PRP)
was obtained by centrifugation at 110 × g for 15 min. Platelet-poor plasma (PPP) was
obtained by another centrifugation of the PRP-removed blood sample at 2730 × g for 15 min
and was used as the blank for aggregation. PRP was incubated for 10 min at 37°C and then
25 μg/mL collagen (Chrono-PAR #385 Havertown, PA) was added. The percentage of
aggregation was determined 3 min after the addition of collagen using Chrono-Log
Aggrolink software.
Flow Cytometery for P-selectin expression—To determine platelet P-selectin
(CD62P) expression, 100 μL diluted blood aliquots (1:100 dilution of blood to Hank’s
Balanced Salt Solution (HBSS) without CaCl2 and MgCl2) were directly prepared for cell
surface staining of P-selectin. In four 12 × 75 polypropylene tubes containing 100 μL of
diluted blood, 40 μg/mL collagen is added to two tubes and 4 μL saline is added to the other
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two tubes. At this point, saturating concentrations (10 μL) of monoclonal antihuman CD62P
PE antibody was added to one collagen and one saline treated tube and incubated for 15 min
at room temperature (RT) in the dark. In the other two tubes containing collagen and saline,
10 μL of IgG1 PE was added as nonbinding isotype control and also incubated for 15 min at
RT in the dark. After the antibody incubation, each tube received 700 μL of freshly prepared
1% formaldehyde buffer (in dPBS) and stored at 4°C until ready for flow cytometric
analysis. A FACSCalibur flow cytometer (Becton Dickinson San Jose, CA) was used for the
acquisition of flow data and the CellQuest software used for data analysis. Cell populations
were identified for data collection by their forward scatter (FSC) and side scatter (SSC) light
profiles. For each sample, 30,000 total events were collected. Fluorescence intensity of
immunostaining was quantitated by histogram log plot analysis. Mean fluorescent intensity
(MFI) was expressed as the geometric mean channel fluorescence minus the appropriate
isotype control.
Determination of thrombus area—After 4 h on ECC, the circuits were clamped,
removed from animal, rinsed with 60 mL of saline, and drained. Any residual thrombus in
the larger tubing of ECC (i.e., thrombogenicity chamber) was photographed and the degree
of thrombus image was quantitated using Image J imaging software from National Institutes
of Health (Bethesda, MD). The animals were euthanized using a dose of Fatal Plus (130 mg/
kg sodium pentobarbital) (Vortech Pharmaceuticals Dearborn, MI).
2.7. Statistical analysis
Data are expressed as mean ± SEM (standard error of the mean). Comparison of ECC results
between the various control polymer groups and NOrel and the control polymer groups were
analyzed by a one-way ANOVA with a multiple comparison of means using Student's t-test.
Values of p < 0.05 were considered statistically significant for all tests.
3. Results and Discussion
3.1 Comparison of hemodynamic effects of four biomedical grade polymers in ECC rabbit
model
The hemocompatibility of Tecophillic SP-60D-60, Tecoflex SG80A, Elast-Eon E2As,
poly(vinyl chloride) (PVC)) polymer coatings was compared using the 4 h rabbit
thrombogenicity model. The goal of this comparison was to choose the polymer with the
best hemocompatible properties to be combined with the NO release chemistry for
optimizing NOrel coatings for extracorporeal circulation testing in rabbits. Polymers were
coated on the ECC tubings as described in Section 2.2. Platelet preservation during exposure
of the coated ECC surfaces to flowing blood was assessed by measuring the platelet count
every hour. Platelet count was used as one of the parameters to assess the hemocompatibility
of the surface because the decrease in the platelet count over time indicates the activation of
platelets on the tubing surface.9, 12, 15 Platelet count was corrected for any hemodilution due
to any IV infusion of fluids into the rabbits. Only 1 out of 5 loops coated with E2As clotted
before the end of the 4 h experiment, whereas, 2-3 of the SP-60D-60, SG80A, and PVC/
DOS loops clotted (4 loops were tested for each polymer). As shown in Fig. 2A, at the end
of 4 h, all polymer coatings exhibited a time dependent loss in platelets, however, 58 ± 3%
of platelets were preserved for E2As ECCs whereas, animals tested with PVC/DOS, SG80A,
and SP-60D-60 exhibited a more significant loss in platelets count (46 ± 3%, 44 ± 4%, 41 ±
5%, respectively). To ascertain the differential of the thrombus in the thrombogenicity
chambers (i.e., the 3/8” Tygon 8 cm in length within the ECC loop) of the coated ECCs, a
two dimensional analysis was performed after 4 h of blood exposure. NIH Image J imaging
software was used to calculate the representative 2-D thrombus area (cm2) in each tubing
chamber.12, 15 The thrombus area of the E2As polymer coated ECC was significantly lower
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than the other polymers tested. These polymers had clot areas of 5.2 ± 0.3, 6.7 ± 0.3, 6.1 ±
0.4, and 6.9 ± 0.2 cm2 for E2As, PVC/DOS, SP-60D-60, and SG80A, respectively (see Fig.
2B). Based on the platelet count and clot area, the E2As polymer was found to have
enhanced intrinsic hemocompatible properties compared to the other polymers. The
preservation of platelet count and reduced clot area can be attributed to the fact that the
E2As polymer binds to albumin more strongly than fibrinogen, which likely aids in
passivating the surface.20 It is widely accepted fact that protein adsorption is the first event
that occurs upon surface-blood contact.21 Fibrinogen is a key protein in the coagulation
cascade that rapidly adsorbs to foreign surfaces and binds to activated platelets. Fibrinogen
contains multiple binding sites for platelet integrin αIIbβ3 (GPIIbIIIa).22, 23 These
fibrinogen-αIIbβ3 interactions play a significant role in platelet adhesion, activation and
aggregation that ultimately leads to a clot formation.23 Platelets can bind to both albumin
and fibrinogen, however albumin can significantly reduce the platelet adhesion in
comparison to fibrinogen coated surfaces.24 The fact that E2As polymer adsorbs albumin
more strongly than fibrinogen indicates its potential in passivating the blood contacting
surfaces though this mechanism.20 This study provided the opportunity to compare various
biomedical grade polymers in order to choose the best candidate material for incorporating
NO donors. Our hypothesis is that by combining the E2As polymer (with excellent intrinsic
hemocompatibility properties) with NO release will further improve the overall
hemocompatibility of such coatings than can be achieved by use of either approach alone.
3.2 Nitric oxide release measurements from E2As-based NOrel coatings and their effects
on rabbit hemodynamics
ECC circuits were coated with the DBHD/N2O2-doped E2As polymer as described in
Section 2.2 above. The NOrel loops were prepared with E2As coating containing 25 wt%
DBHD/N2O2, and 10 wt% 5050DLG7E PLGA additive. This ratio of DBHD/N2O2 and
5050DLG7E PLGA additive was found to be optimal in our previous work with PVC
coatings.15 The combined E2As-based NOrel coating material continuously releases NO
under physiological conditions for greater than 4 h at levels that exceeds the physiological
NO flux levels from endothelial cells (0.5-4 × 10−10 mol cm−2 min−1).8 The NO release, as
measured using chemiluminescence NO analyzer, shows an average sustained NO flux of
approximately 6 × 10−10 mol cm−2 min−1 for 4 h (Fig. 3). The NOrel coated ECCs exhibited
a slight burst of NO upon initial exposure to the PBS and 37°C that lasted ~ 30 min.
Therefore, the ECC loops were first soaked with PBS for 30 min prior to the rabbit
experiments in order to reduce the effects of this burst. The NO flux from the surface of the
ECC circuit does not decrease significantly after exposure to the flowing blood. Indeed, after
4 h of blood flow, the NO flux was found to be 5 × 10−10 mol cm−2 min−1. The fact that the
blood environment does not alter the kinetics of the NO release from the coating agrees well
with the previously reported data for various NO release ECC circuits.12, 15
No significant difference in the mean arterial pressure (MAP) of the animals on the NOrel
vs. control circuits was noted, with pressures averaging 45±5 mm Hg for both types of
circuits. Heart rates for the NOrel and control ECC groups were unchanged over the 4 h time
period. The ECC blood flow was maintained at approximately 110 mL/min for the NOrel
circuits over the 4 h animal test period. However, the blood flow dropped from the initial
110 mL/min to approximately 75 mL/min in the first one hour for the control circuits, and
then further dropped to 60 mL/min over the next 3 h period. Intravascular fluids were
maintained at 10 mL/kg/min to maintain the blood flow in both NOrel and control circuits.
The activation clotting time for blood obtained from the test animals increases over the 4 h
period for both NOrel and control coated circuits. As noted in previous studies,12 this
behavior can be attributed to the increase in intravascular fluids and concomitant
hemodilution effect.
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3.3. Effects of E2As-based NOrel coating on rabbit platelet function and thrombus
formation in a short-term (4 h) application
The short-term 4 h rabbit ECC model was used to observe the effects of the NOrel coating
on platelet count, platelet function, and clotting. As described in Section 2.6, platelet
activation and function throughout the 4 h ECC was assessed by recording the platelet count
and platelet aggregation, which were both corrected for hemodilution due to the added IV
fluids. For NOrel coated ECC loops, all 5 survived the 4 h experiment, whereas for E2As
control only 4 out of 5 loops survived the 4 h ECC run. For the NOrel circuits, the platelet
count rose slightly above the baseline value during the first hour, likely due to the release of
reserve platelets from the spleen. The platelet count returned to the baseline level during the
second hour and was maintained at an average of 97 ± 10% of baseline levels at the end of
the 4 h experiments. The platelet count for E2As control circuits showed a time-dependent
loss in platelets dropping to 58 ± 3% of baseline after 4 h (Fig. 4A). As shown in Fig. 4B, a
significant reduction of clot area was observed on NOrel (0.9 ± 0.3 cm2) as compared to
E2As controls (5.2 ± 0.3 cm2).
Platelet function during exposure to NOrel and E2As control polymer coated ECCs was also
assessed by percentage of aggregation, as determined by ex vivo collagen-stimulated of PRP
and measured by optical turbidity12, 15 over the course of the 4 h ECC experiment (Fig. 5).
The NOrel polymer ECC showed a greater preservation of platelet aggregation over the
course of 4 h blood exposure, while the E2As control polymer showed a significant loss in
ability to aggregate upon collagen stimulation at the 4 h time point. The ability to aggregate
upon exogenous collagen stimulation was maintained with NOrel ECCs at 91% of baseline
values after 4 h, whereas the platelets from control ECCs had only 49% ability to aggregate.
This data is in agreement with the observation by Major et al., who previously showed that
NOrel materials have the ability to preserve platelet function and their ability to aggregate.12
To further evaluate the effects of the ECC loops, platelet P-selectin (CD62P) expression was
used as an early activation marker to test the hemocompatibility of the ECC loops. In order
to ascertain the differential expression of the platelet adhesion glycoprotein, P-selectin,
between the NOrel and E2As control polymer coated ECCs, fluorescence-activated cell
sorting (FACS) analysis was performed on rabbit circulating platelets. A gated region is
chosen on forward scatter (FSC) vs. side scatter (SSC) dot plot which is representative of the
circulating platelet population and the same gate was used in all subsequent FACS analysis
for CD62P expression. When platelets become activated, the surface expression of P-
selectin increases.25 The platelet P-selectin surface expression data is shown via mean
fluorescence intensity (MFI) in Fig. 6. P-selectin expression was considerably elevated on
unstimulated control ECC platelets in comparison to the NOrel ECC platelets with respect to
the baseline values. This indicates higher platelet activation in the case of control vs. NOrel
surfaces after 4 h ECC blood exposure. Addition of collagen (40 μg/mL) significantly
stimulated an increase in P-selectin expression at baseline and after 4 h on control and
NORel ECCs, indicating proper functioning of the platelets after NO exposure. This data
indicates that NO flux of 6 × 10−10 mol cm−2 min−1 was sufficient to keep the protein
markers of platelet activation quiescent for the 4 h period without adversely affecting their
functionality.
In the previous work it was shown that using DBHD/N2O2 chemistry in PVC/DOS polymer
an NO flux of approximately 10 – 15 × 10−10 mol cm−2 min−1 is needed to prevent clotting
and maintain 80% of baseline platelet count in extracorporeal circulation.12, 15 Here we
report that with the appropriate polymer, such as E2As, an NO flux of only 6 × 10−10 mol
cm−2 min−1 is sufficient to prevent platelet activation, reduce clot area, and is able to
maintain 97% of baseline platelet count at the end of 4 h, showing a significant
improvement over our previous work.
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5. Conclusions
This study reports on a comparison of four biomedical polymers with respect to their
inherent ability to resist platelet consumption and thrombus formation in 4 h ECC rabbit
model. Elast-Eon E2As was found to be superior to SP-60D-60, SG80A, and PVC/DOS, in
prevention of thrombus formation in the short-term rabbit model. Nitric oxide release from
optimal E2As coatings containing a diazeniumdioloate NO donor and PLGA additive on the
inner walls of the ECC circuits was able to further attenuate the activation of the platelets
while maintaining their functionality in a 4 h ECC rabbit model and reduce clot area. We
were also able to demonstrate that a lower flux of NO is sufficient to maintain platelet count
and reduce clotting when using circuits prepared with a more hemocompatible base polymer
coating such as E2As as compared to our previous work where other polymers such as PVC/
DOS was employed as the base polymer. These encouraging results demonstrate that E2As-
based NOrel materials have great potential to improve the hemocompatibility of both short
and potentially long-term blood contacting devices such as catheters, vascular grafts, stents
and other extracorporeal life support devices. These E2As based NOrel coatings are
currently under investigation for longer-term catheter applications.
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Fig. 1.
Diagram of the extracorporeal circuit (ECC) tubing coated with (A) base polymers PVC/
DOS, SP-60D-60, SG80A, or E2As, and (B) E2As doped with a lipophilic DBHD/N2O2 and
the PLGA additive with a top coat of E2As.
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Fig. 2.
(A) Comparison of time-dependent effects of 4 base polymers coated ECC loops on platelet
consumption. * = p < 0.05, E2As vs. other polymers; # = p < 0.05, E2As vs. PVC/DOS and
SG80A; & = p < 0.05, E2As vs. PVC/DOS. (B) Quantitation of thrombus area as calculated
with NIH ImageJ software using a 2D representation of thrombus. The data are means ±
SEM. * = p < 0.05, E2As vs. other polymers.
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Fig. 3.
Representative NO surface flux profiles from E2As base NOrel polymer ECC containing
DBHD/N2O2 at 37 °C and pH 7.4 obtained via chemiluminescence detection method.
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Fig. 4.
(A) Time dependent effects of NOrel ECC (25 wt% DBHD/N2O2 + 10 wt% 5050DLG7E
PLGA in E2As) as compared to control ECC on rabbit platelet count (i.e. consumption) as
measured via Coulter counter. (B) Quantitation of thrombus area as calculated with NIH
ImageJ software using a 2D representation of thrombus. The data are means ± SEM. * = p <
0.05, control vs. NOrel ECC circuits.
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Fig. 5.
Time-dependent effects of NOrel vs. control polymer ECC on platelet function, as measured
via aggregometry. The data are means ± SEM. * = p < 0.05, control vs. baseline; # = p <
0.05, control vs. NOrel ECC circuits.
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Fig. 6.
Platelet P-selecting mean fluorescent intensity after 4 h on ECC with or without 40 μg/mL
collagen stimulation in E2As-based NOrel and E2As control coatings.
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